Emergent BioSolutions Inc.

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Emergent BioSolutions will host a ribbon cutting ceremony on September 16, 2026 at its Canton, Massachusetts facility to mark the site's manufacturing restart and growth. Emergent plans to add approximately 50 manufacturing, technical and operational positions as part of its investment in the Canton site. CEO Joe Papa and manufacturing SVP Bill Hartzel will speak alongside Massachusetts economic development officials, with the event framed around strengthening domestic manufacturing capabilities and public health preparedness.

•1mo ago

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Emergent BioSolutions completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, deploying roughly $68 million of cash at an average price of 90.6% of face value. The repurchase trims the outstanding principal balance to approximately $364.7 million ahead of the notes' August 2028 maturity, with management saying it will keep monitoring market conditions for the optimal refinancing timing. Emergent cites a strong cash position plus $50 million of additional availability under its asset-based revolving loan facility, and executives will discuss the milestone and broader transformation progress at the Wells Fargo and H.C. Wainwright healthcare conferences this month.

•1mo ago

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Emergent BioSolutions secured a contract modification valued at approximately $24 million from BARDA to supply its CYFENDUS vaccine for anthrax preparedness efforts. The award builds on the company's existing relationship with the U.S. government, following a prior $21.5 million delivery order for BioThrax earlier this year. Management emphasized that the modification highlights the continued importance of maintaining readiness against anthrax threats and supports reliable domestic manufacturing capabilities.

•2mo ago

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Emergent BioSolutions secured a standing offer from the Government of Canada to supply NARCAN Nasal Spray effective October 1, 2026 through September 30, 2029, with an option to extend for two additional years. The agreement follows an expiring five-year standing offer and allows federal, provincial, and territorial organizations to procure the medication through individual call-ups. Management highlighted that the selection reinforces the company's commitment to expanding access to life-saving overdose treatments.

•2mo ago

Emergent BioSolutions Commits to Cross-Sector Collaboration Against Biological Threats in an Evolving Global Security Environment

Emergent BioSolutions emphasized the growing importance of biodefense preparedness amid rising concerns over AI-enabled biological threats and geopolitical instability, citing warnings from European health officials and U.S. AI leaders. The release highlights a new NEJM Evidence study reinforcing the value of Emergent's CYFENDUS vaccine for post-exposure prophylaxis following recent anthrax outbreaks. CEO Joe Papa stated that the company remains committed to collaborating with government and industry leaders to strengthen global safeguards against these evolving risks.

•2mo ago

Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Support U.S. Biodefense Strategy

Emergent BioSolutions was awarded a $64.5 million contract modification from the U.S. Department of Health and Human Services for its BAT botulism antitoxin. The modification extends an existing 10-year contract with the Administration for Strategic Preparedness and Response (ASPR) to supply the antitoxin for biodefense preparedness. This win reinforces Emergent’s role as a key supplier of medical countermeasures to the U.S. government, supporting both military and civilian populations against potential botulism threats.

•5mo ago

Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live]

Emergent BioSolutions announced that the Saudi Food and Drug Authority (SFDA) has approved ACAM2000 for the prevention of smallpox and mpox in high-risk individuals. This marks the first Emergent product licensed by the SFDA, signaling expanded government adoption in the Gulf region. The approval follows a recent expanded indication approval in Singapore, reinforcing the global regulatory momentum for the company's biodefense portfolio.

•5mo ago

Emergent BioSolutions Reports First Quarter 2026 Financial Results

Emergent BioSolutions reported Q1 2026 revenue of $156.1 million, a 30% decrease year-over-year, but stated it was above the high-end of guidance. Adjusted EBITDA was $35.6 million. The company raised its full-year 2026 guidance for Adjusted EBITDA to $155-$175 million and Adjusted Net Income to $45-$65 million, while maintaining total revenue guidance of $720-$760 million. A new $150 million term loan facility was secured to refinance debt and reduce interest expense. Business updates included new manufacturing partnerships with Substipharm Biologics and SAB Biotherapeutics, over $200 million in new government contracts, and the authorization of a $50 million share repurchase program.

•6mo ago

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

Emergent BioSolutions entered a multi-year agreement with SAB Biotherapeutics valued at approximately $50 million to support the process development and manufacturing of SAB-142 for type 1 diabetes. The contract leverages Emergent's Winnipeg facility for end-to-end services, including technology transfer and commercial manufacturing, contingent upon regulatory approval. Of the total deal value, $36 million is performance-based, tied to future regulatory approvals and downstream milestones for the SAB-142 program.

•6mo ago

Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States

Emergent BioSolutions entered a strategic manufacturing agreement with Substipharm Biologics valued at approximately $34.5 million to produce the Japanese Encephalitis vaccine IMOJEV at its Canton facility. The deal grants Emergent exclusive distribution rights to the U.S. government upon potential FDA approval, leveraging the facility's recent "No Action Indicated" status following a February inspection. Emergent has initiated scale-up efforts at the Canton facility and plans to hire additional employees later this year to support the partnership.

•6mo ago